OEM News

Humabiologics Receives Grant for First Human Collagen Matrix for Regenerative Applications

Humabiologics will be collaborating with the Wake Forest Institute for Regenerative Medicine and other members of the PTRME.

Author Image

By: Rachel Klemovitch

Assistant Editor

Humabiologics, Inc., a leading innovator in human-derived biomaterials for regenerative medicine, has been selected as one of six companies to receive an inaugural grant from the Piedmont Triad Regenerative Medicine Engine (PTRME). This $2.5 million investment is funded by the National Science Foundation (NSF) and will help drive forward the Piedmont Triad region’s regenerative medicine industry.

Funding will go towards accelerating its development of human collagen biomanufacturing of the market’s first human collagen matrix for various regenerative medicine applications. 

The PTRME is a regional driving force in translating groundbreaking research into real-world regenerative medicine solutions and is located in the Piedmont Triad region.

“We are honored to be recognized by PTRME for our work in human collagen biomanufacturing,” said Dr. Mohammad Albanna, principal investigator of the grant and Founder & CEO of Humabiologics. “This grant will be instrumental in advancing our clinical translational effort, allowing us to explore the full potential of human collagen as a new class of biomaterial for regenerative medicine beyond research for clinical applications.”

Humabiologics will be collaborating with the Wake Forest Institute for Regenerative Medicine (WFIRM) and other members of the PTRME. The company is dedicated to pushing the boundaries of biomaterial science to develop cutting-edge solutions for regenerative medicine, contributing to the development of a thriving regenerative medicine ecosystem in the Piedmont Triad region, and ultimately translating innovation into real-world improvements in patient health and well-being.

“We are proud to see companies like Humabiologics’ thrive within the PTRME ecosystem. Their efforts highlight our dedication to commercializing research, driving advancements in regenerative medicine, and fostering future manufacturing employment opportunities,” said Tim Bertram, PTRME CEO.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics